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Abstract
Objectives. To identify factors associated with FM development and recovery in patients with axial SpA (axSpA).
Methods. The British Society of Rheumatology Biologics Register for Ankylosing Spondylitis (BSRBR-AS) recruited
patients with axSpA from 83 centres in a prospective study. FM was diagnosed using the self-reported
Fibromyalgia Survey Diagnostic Criteria from 2015. Measures of axSpA disease activity and clinical findings were
recorded at regular intervals. We identified predictors for FM development and recovery between yearly visits using
uni- and multivariable logistic regression models.
Results. A total of 801 participants, 247 (30.8%) female, had two or more visits and were eligible for inclusion. A
total of 686 participants did not have FM at baseline, of whom 45 had developed FM at follow-up, while 115 par-
ticipants had FM at baseline, of whom 77 had recovered at follow-up. A high baseline BASDAI score [odds ratio
(OR) 1.27 (95% CI 1.08, 1.49)] and Widespread Pain Index (WPI) [OR 1.14 (95% CI 1.02, 1.28)] were significantly
associated with FM development in the final multivariable model. A low baseline BASFI score [OR 0.68 (95% CI
0.53, 0.86)] and WPI [OR 0.84 (95% CI 0.720, 0.97)] and starting a TNF inhibitor [OR 3.86 (95% CI 1.54, 9.71)]
were significantly associated with FM recovery.
Conclusion. High levels of disease activity and the presence of widespread pain is associated with the develop-
ment of FM in patients with axSpA, while low levels of the same variables and starting a TNF inhibitor are associ-
ated with recovery from FM. The presence of comorbid FM should be considered in patients with persistent high
axSpA disease activity and widespread pain.
Key words: spondyloarthritis, fibromyalgia, trajectories, disease activity
Introduction
Axial SpA (axSpA) is a chronic inflammatory disease
associated with the presence of HLA-B27 [1]. AxSpA
may affect the sacroiliac joints, spine and peripheral
joints and the pathological process leads to the forma-
tion of new bone. Most untreated patients will eventually
suffer from limited mobility of the spine that may cause
pain and physical dysfunction [1, 2]. AS is a form of
axSpA that can be diagnosed by the modified New York
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. In patients with axial spondyloarthritis (axSpA), comorbid fibromyalgia (FM) is not usually a permanent state.
. High levels of axSpA disease activity are associated with developing FM.
. Patients with low levels of axSpA disease activity or who experience a change in disease activity through starting
a TNF inhibitor are more likely to recover from FM.
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(mNY) criteria [3]. The mNY criteria require radiological
evidence of sacroiliitis. In recent years the Assessment
of SpondyloArthritis international Society (ASAS) has
developed classification criteria for axSpA that do not
require sacroiliitis to be visible on conventional radio-
graphs [4]. FM is a disorder of pain perception charac-
terized by widespread pain and fatigue. There are many
additional symptoms, including lack of concentration,
autonomic dysfunction and abdominal pain [5]. In the
general population, FM should be diagnosed promptly
and patients should be offered treatment for the condi-
tion [6].
The estimated prevalence of coexisting FM in axSpA
is 14% (95% CI 8, 20) according to a recent meta-
analysis [7]. The identification of comorbid FM in
patients with axSpA could be especially important in the
current treat-to-target era, as the presence of FM may
interfere with the patient’s self-assessment of treatment
response [8, 9]. We have previously shown that patients
with axSpA and FM report higher levels of axSpA dis-
ease activity, depression, anxiety, fatigue and work
interference compared with patients with axSpA alone
[10]. The presence of FM also contributes negatively to
the quality of life of these patients [11]. However, FM in
axSpA may not be a permanent state, and studies have
reported that 50% ‘recover’ following the start of TNF
inhibitor (TNFi) treatment [8, 9].
The identification of predictors for longitudinal FM de-
velopment has been identified as a research priority in a
recent systematic review and meta-analyses [7] and the
change in the FM state is of particular interest. This art-
icle examines the longitudinal factors associated with
FM development and recovery in patients with axSpA.
Methods
The British Society of Rheumatology Biologics Register
for Ankylosing Spondylitis (BSRBR-AS) is a prospective
cohort study that recruited biologic therapy–naı̈ve
patients fulfilling the ASAS criteria for axSpA [8].
Participants were recruited from 83 secondary care
rheumatology centres across the UK between
December 2012 and December 2017 and the full proto-
col has been published previously [12]. Visits were
scheduled at 3 and 6 months for participants commenc-
ing TNFi therapy and then yearly for the whole cohort.
At each visit the presence of extraspinal manifestations,
history of 14 prespecified common comorbidities and
BASMI score were recorded and blood samples were
analysed for inflammatory markers (CRP and ESR). In
addition, the following patient-reported questionnaires
were mailed to participants at the time of each visit:
BASDAI, BASFI, Hospital Anxiety and Depression Scale
(HADS; score 0–21) [10], (Chalder Fatigue Scale (score
0–11) [11] and the Jenkins Sleep Evaluation
Questionnaire (score 0–20) [12].
The 2010 ACR Fibromyalgia Preliminary Diagnostic
Criteria introduced the possibility of diagnosing FM
using a self-reported questionnaire, in contrast to the
1990 classification criteria for FM (FM 1990) that
required pain in 11 of 18 tender points upon digital
palpation [5, 13]. The 2011 version of the Fibromyalgia
Survey Diagnostic Criteria (FSDC), a modification of the
2010 criteria that has been validated for use in epi-
demiological surveys, was included in the BSBR-AS
postal questionnaires from August 2015(14). The FSDC
includes a Symptom Severity Scale (SSS) and a
Widespread Pain Index (WPI). The SSS is the sum of
self-reported fatigue, cognitive symptoms, waking unre-
freshed (each scored on a 0–3 scale) and the presence
of headache, abdominal pain and depression [graded as
present (1) or absent (0)] [5, 14]. The WPI is scored as
the number of areas where the patient has experienced
pain during the past week, graded 0 (best) to 19 (worst).
The diagnostic criteria are met if the SSS is 5 and the
WPI is 7 or the SSS is 9 and the WPI is 3–6 [5]. The
2016 update of the FSDC clarified that a diagnosis of
FM may be made in participants with concurrent rheum-
atic disease [15]. It also added a stipulation that the
pain should be present in at least four of five regions
and that the self-reported version is not valid for making
a clinical diagnosis in individuals but is valid for research
purposes.
In this study we refer to ‘FM development’ as the
change in individuals from not fulfilling to fulfilling
the 2016 FSDC and, conversely, ‘FM recovery’ is the
change from fulfilling to not fulfilling the 2016 FSDC. We
included participants who had participated at more than
one visit with a minimum 10 month interval between
consecutive visits. In order for the visit to be eligible, the
patient should have completed the FSDC within
4 months of a clinical visit. The FSDC score was the
main outcome variable of interest.
Statistics
We identified factors associated with FM development
and recovery in participants with axSpA. Baseline demo-
graphics were compared between participants who did
and did not develop FM and between those who did
and did not recover from FM using bivariable analyses
with Bonferroni corrections. The chi-squared test,
Mann–Whitney U test and independent-samples
Student’s t-test were used as appropriate.
Separate logistical regression models were constructed
to identify factors associated with FM development and
recovery. Demographic and FM- and axSpA-related fea-
tures were tested consecutively in univariable models
that were adjusted for age and gender. Variables that
were related to the outcome with a P-value 0.1 were
then included in the multivariable model and a backwards
regression was performed until all variables were signifi-
cantly associated with the outcome at P< 0.05. Age and
gender were forced into all models. Separate multivari-
able models were constructed for FM- and axSpA-related
variables.
Random effect maximum likelihood linear regression
models, accounting for repeated measures, were
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constructed for participants who had three consecutive
visits, to identify factors associated with SSS and WPI
levels. In addition, we examined longitudinal change in
the SSS and WPI over time.
Several sensitivity analyses were performed, including
stratification. The main multivariable analyses for FM de-
velopment were stratified for participants who did and
did not start on TNFi during the observation period and
for participants who did and did not fulfil the mNY crite-
ria for AS. Additionally, we repeated the main analyses
using the 2011 FSDC to diagnose FM.
Results
A total of 2687 participants who were starting on a first
TNFi or who were continuing a conventional synthetic
DMARD (csDMARD) were included in the BSRBR-AS
study and 1285 had at least one follow-up visit. A total
of 801 participants (29.8% of the total number of partici-
pants in the BSRBR-AS) were eligible for inclusion with
a minimum of two completed visits at a 10 month
interval; of these, 138 participants had three visits
(Supplementary Fig. S1, available at Rheumatology on-
line). The median age at baseline was 51.4 years [inter-
quartile range (IQR) 39.9–62.2], the median symptom
duration was 9 years (IQR 3–22) and 67.7% were male
(554/801). HLA-B27 was available in 598 patients and
482 (80.6%) were positive. Of eligible participants, 534
(66.7%) fulfilled the mNY criteria for AS, 225 (28.1%)
met the ASAS imaging criteria but not the mNY criteria
and 42 (5.2%) met only the ASAS clinical criteria for
axSpA. The median number of months between the first
and second visit was 12.5 (IQR 11.8–14.7) and 24.4 (IQR
23.7–25.7) between baseline and the third visit. Baseline
demographics are presented in Table 1.
The median baseline SSS was 5 (IQR 3–7) and 90%
of participants had an SSS 9 at all visits. The median
WPI was 4 (IQR 2–6) and 70% of the participants had a
WPI 7 at baseline and all visits.
Fig. 1 shows an illustration of the changing states of
FM between baseline and the 1 year follow-up. A total of
686 participants did not fulfil the FM criteria at baseline;
of these, 45 (6.6%) fulfilled the criteria at the first follow-
up visit (Table 1). In bivariable analyses, participants
who developed FM had higher baseline BASDAI and
BASFI scores and more FM-related symptoms com-
pared with participants who did not develop FM.
A total of 115 participants fulfilled the FM criteria at
baseline; of these, 77 (70%) did not fulfil the criteria at
the follow-up (Table 2). Patients who recovered from FM
had lower baseline BASFI scores compared with
patients with permanent FM (Table 2).
Baseline variables associated with longitudinal FM
development in participants without FM at baseline
In multivariable logistic regression models (Table 3), the
axSpA features associated with FM development were
the absence of HLA-B27 and high baseline BASDAI
scores, while high WPI and HADs anxiety scores were
the FM-related variables that were significantly associ-
ated with FM development. In the final multivariable
models, baseline BASDAI [OR 1.27 (95% CI 1.08, 1.49)]
and WPI [OR 1.14 (95% CI 1.02, 1.28)] scores remained
significantly associated with the outcome.
Baseline factors associated with longitudinal FM
recovery in participants without FM at baseline
In multivariable logistic regression models (Table 4) the
baseline axSpA-related features that were associated
with FM recovery were low BASFI score and starting on
a TNFi, whereas the FM-related variables that were
most strongly associated with FM recovery were low
WPI and Jenkins Sleep Evaluation scores. In the final
multivariable logistic regression model, baseline BASFI
TABLE 1 Baseline demographics
Variables n Values
Age, years, median (IQR) 801 51.4 (39.9– 62.2)
Male, n (%) 801 554 (67.7)
Symptom duration, years, median (IQR) 772 9.0 (3–22)




Further education (college) 150 (20.0)
University degree 75 (10.0)
HLA-B27 positive, n (%) 598 482 (80.6)
Criteria fulfilled, n (%) mNY 801 534 (66.7)
ASAS imaging 225 (28.1)
ASAS clinical 42 (5.2)
BMI, kg/m2, mean (S.E.) 519 26.7 (24.0–30.5)
Met 2016 FSDC, n (%) 801 115 (14.4)
BASDAI score, median (IQR) 796 4.1 (2.1–6.0)
Comorbidities present, n (%) 801 213 (26.6)
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FIG. 1 The changing states of FM between the baseline visit and 1 year follow-up visit. FM: 2016 FSDC
TABLE 2 Bivariable comparison between changing states of FM
Variables Participants who did not fulfil
the FSDC at baseline (n 5 686)
Participants who fulfilled the




FM (n 5 45)
P-value n Recovered from
FM (n 5 77)
Permanent
FM (n 5 38)
P-value
Age, years, mean (S.E.) 686 51.04 (0.55) 51.39 (2.31) 0.87 115 49.80 (1.90) 52.27 (2.37) 0.46
Female, n (%) 686 195 (30.42) 20 (44.44) 0.05 115 29 (37.66) 15 (39.47) 0.85
Duration, years, mean (S.E.) 686 13.92 (0.52) 11.91 (2.08) 0.10 86 11.39 (1.30) 10.29 (1.91) 0.63
Education, mean (S.E.) 643 2.74 (0.06) 2.73 (0.21) 0.96 109 2.54 (0.14) 2.23 (0.21) 0.22
BMI, kg/m2, mean (S.E.) 448 27.10 (0.23) 27.87 (1.28) 0.80 54 27.44 (0.94) 29.28 (1.51) 0.29
Comorbidities, n(%) 686 155 (24.18) 12 (26.67) 0.71 115 33 (42.86) 13 (34.21) 0.37
SpA-related features
HLA-B27 positive, n (%) 525 411 (83.7) 22 (64.71) 0.005 73 35 (76.09) 14 (51.85) 0.03
Sacroiliitis CXR, n (%) 571 456 (84.76) 26 (78.79) 0.36 95 51 (76.69) 26 (83.87) 0.63
Sacroiliitis MRI, n (%) 457 327 (76.76) 29 (93.55) 0.03 80 45 (88.24) 25 (86.21) 0.79
Uveitis, n(%) 672 112 (17.83) 6 (13.64) 0.48 115 20 (25.97) 5 (13.16) 0.12
CRP, mg/dl, mean (S.E.) 499 2.11 (0.29) 0.98 (0.21) 0.81 87 1.77 (0.61) 1.91 (0.74) 0.68
ESR, mean (S.E.) 333 14.49 (0.92) 13.18 (1.99) 0.55 52 11.77 (2.65) 18.76 (3.94) 0.07
BASDAI, mean (S.E.) 681 3.71 (0.09) 5.47 (0.30) <0.001* 115 6.14 (0.18) 6.87 (0.36) 0.04
BASMI, mean (S.E.) 461 3.56 (0.09) 3.81 (0.38) 0.54 69 4.58 (0.24) 4.80 (0.55) 0.54
BASFI, mean (S.E.) 684 3.64 (0.10) 4.97 (0.40) 0.001* 115 6.01 (0.23) 7.42 (0.39) 0.001*
ASDAS-CRP, mean (S.E.) 443 1.07 (0.06) 1.71 (0.20) 0.01 73 1.83 (1.11) 2.45 (0.29) 0.05
Started on TNFi, n (%) 686 127 (19.81) 15 (33.33) 0.03 115 43 (55.84) 12 (31.58) 0.01
Months on TNFi, mean (S.E.) 151 11.30 (0.46) 9.53 (0.93) 0.18 46 11.23 (0.90) 9.48 (1.57) 0.33
FM-related features
SSS, mean (S.E.) 614 4.45 (0.11) 6.30 (0.42) <0.001* 96 7.85 (0.24) 8.83 (0.33) 0.02
WPI, mean (S.E.) 686 3.74 (0.11) 5.91 (0.44) <0.001* 115 9.13(0.30) 10.66 (0.55) 0.01
Anxiety, mean (S.E.) 581 5.94 (0.17) 8.31 (0.64) <0.001* 86 9.39 (0.50) 10.34 (0.91) 0.32
Chalder fatigue scale, mean
(S.E.)
548 2.81 (0.13) 4.49 (0.56) 0.003 115 5.78 (0.39) 6.89 (0.61) 0.08
Jenkins Sleep Evaluation,
mean (S.E.)
544 8.51 (0.23) 10.91 (0.82) 0.01 115 12.71 (0.62) 15.44 (0.81) 0.005
Comparison between participants who do not develop FM and those who develop FM and between those who recover
from FM and those who still have FM after 1 year of observation using the 2016 FSDC. *Significant after Bonferroni correc-
tion. All groups are mutually exclusive. Duration: years since the first visit to a rheumatologist; CXR: conventional
radiography;
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score [OR 0.68 (95% CI 0.53, 0.86)], starting on TNFi
[OR 4.23 (95% CI 1.63, 11.00)] and WPI score [OR 0.84
(95% CI 0.72, 0.97)] were significantly associated with
FM recovery (Table 4).
Longitudinal mixed models
A total of 138 participants had three visits with at least
10 month intervals. A total of 128 (92.8%) participants
did not have FM at baseline, but 4 of these fulfilled the
diagnostic criteria at the third visit. Of the 10 (7.2%) par-
ticipants who had FM at baseline, 5 did not meet the
diagnostic criteria at the third visit.
In longitudinal mixed models that examined factors
associated with the components of the FSDC over time,
BASDAI and BASFI scores were both significantly asso-
ciated with SSS and WPI, while the BASMI score was
significantly associated with WPI (Table 5). Over the
24 month period, the median change in SSS was 0 (IQR
1–2) and the median change in WPI was 0 (IQR 2–2).
There was no evidence of a longitudinal trend in change
in either the SSS [b-coefficient for time in months 0.00




Baseline WPI was the only variable significantly associ-
ated with developing FM in multivariable models that
were restricted to participants who started a TNFi
(Supplementary Table S1, available at Rheumatology on-
line). Baseline BASDAI was the only variable significantly
associated with developing FM in multivariable analyses
that were restricted to participants who did not start a
TNFi (Supplementary Table S1, available at
Rheumatology online). The baseline variables associated
with FM development were very similar in multivariable
models that were stratified across in participants who
did and did not fulfil the mNY criteria (Supplementary
Table S2, available at Rheumatology online).
Alternative diagnostic criteria for FM
The analyses for this article were repeated using the
2011 FSDC and the results are presented in


















Age (years) 686 1.01 (0.98, 1.03) 1.01 (0.99, 1.03) 1.00 (0.98, 1.03) 1.00 (0.98, 1.03)
Female 686 1.89 (1.01, 3.53)** 2.61(1.27, 5.35)** 1.91 (0.91, 4.00)* 2.04 (0.99, 4.21)*
Years since first contact 686 0.98 (0.95, 1.01)
Education 643 0.98 (0.77, 1.23)
Number of comorbidities 448 1.11 (0.55, 2.22)
BMI (kg/m2) 686 1.02 (0.94, 1.10)
SpA-related features
HLA-B27 positive 525 0.37 (0.18, 0.80)** 0.44 (0.20, 0.98)**
Sacroiliitis present on CXR 571 0.73 (0.29, 1.80)
Sacroiliitis present on MRI 457 3.85 (0.89, 16.60)*
History of uveitis 672 0.71 (0.29, 1.71)
CRP (mg/dl) 499 0.91 (0.76, 1.08)
ESR 333 0.99 (0.96, 1.02)
BASDAI 681 1.39 (1.21, 1.60)*** 1.43 (1.22, 1.68)*** 1.27 (1.08, 1.49)**
BASMI 461 1.05 (0.83, 1.33)
BASFI 684 1.22 (1.08, 1.38)**
ASDAS-CRP 443 1.47 (1.11, 1.95)**
Started on TNFi 686 1.95 (0.92, 4.15)*
Months on TNFi 151 0.87(0.751, 1.01)*
FM-related features
SSS 614 1.28 (1.13, 1.45)***
WPI 686 1.24 (1.13, 1.36)*** 1.22 (1.11, 1.35)*** 1.14 (1.02, 1.28)**
HADS anxiety 581 1.12 (1.05, 1.20)** 1.10 (1.02, 1.18)**
Chalder Fatigue Scale 548 1.14 (1.05, 1.24)**
Jenkins Sleep Evaluation
baseline
544 1.07 (1.01, 1.13)**
ROC/sensitivity/specificity 614 0.75/64.4/75.6 0.78/67.7/78.0 0.75/55.6/75.6
Logistic regression models. Interaction term between HLA-B27 and started on TNFi near significant at 0.05. *P<0.1,
**P<0.05, ***P<0.001. CXR: conventional radiography; ROC: receiver operating characteristics curve.
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Supplementary Tables S3–S5, available at Rheumatology
online. There are no important differences between the
2016 and 2011 FSDC models.
Discussion
In patients with axSpA, baseline levels of axSpA disease
activity and widespread pain both contribute to FM de-
velopment and recovery. Starting on a TNFi is associ-
ated with recovering from FM. The coexistence of FM in
patients with axSpA has previously been found to be
associated with high levels of axSpA disease activity in
cross-sectional studies [16, 17]. The current study adds
to this body of knowledge by providing evidence that
while high levels of axSpA disease activity are associ-
ated with future FM development, low levels of axSpA
disease activity are associated with recovery from FM.
The strength of this study is the large multicentre de-
sign, longitudinal follow-up and comprehensive data col-
lection. There are several weaknesses that should be
considered. We have included a relatively low proportion
of the total number of patients in the BSRBR-AS. This
was mainly due to the fact that the FSDC was only
recorded from 2015 and that only about half of the
patients in the register came for a follow-up visit within
the time frame stipulated. The relationship between
starting a TNFi, clinical data and the self-reported


















Age (years) 115 1.00 (0.97, 1.02) 1.00 (0.97, 1.02) 1.03 (0.99, 1.06) 1.02 (0.99, 1.06)
Female 115 0.90 (0.40, 2.04) 1.29 (0.53, 3.13) 1.03 (0.42, 2.52) 1.20 (0.48, 3.03)
Years since first contact 86 1.02 (0.97, 1.06)
Education 109 1.27 (0.89, 1.80)
Number of comorbidities 54 1.49(0.65, 3.40)
BMI (kg/m2) 115 0.93 (0.86, 1.01)*
SpA-related features
HLA-B27 positive 73 3.14 (1.11, 8.88)**
Sacroiliitis present on CXR 95 0.64 (0.12, 2.13)
Sacroiliitis present on MRI 80 1.18 (0.30, 4.62)
History of uveitis 115 2.51 (0.83, 7.60)
CRP (mg/dl) 87 0.99 (0.89, 1.10)
ESR 52 0.98 (0.95, 1.02)
BASDAI 115 0.79 (0.63, 1.00)**
BASMI 69 0.88 (0.65, 1.19)
BASFI 115 0.70 (0.56, 0.88)** 0.66 (0.53, 0.84)** 0.68 (0.53, 0.86)**
ASDAS-CRP 73 0.63 (0.39, 1.01)*
Started on TNFi 115 2.78 (1.21, 6.38)** 3.86 (1.54, 9.71)** 4.23 (1.63, 11.00)**
Months on TNFi 46 1.08 (0.96, 1.21)
FM-related features
SSS 96 0.76 (0.61, 0.96)**
WPI 115 0.84 (0.73, 0.96)** 0.84 (0.73, 0.97) 0.84 (0.72, 0.97)**
HADS anxiety 86 0.96 (0.88, 1.04)
Chalder Fatigue Scale 115 0.91(0.81, 1.02)
Jenkins Sleep Evaluation
baseline
115 0.90 (0.83, 0.98)** 0.90 (0.83, 0.98)
ROC/sensitivity/specificity 96 0.68/50.7/68.4 0.76/45.4/79.0 0.78/62.3/73.7
Logistic regression models. *P<0.1, **P<0.05. CXR: conventional radiography; ROC: receiver operating characteristics
curve.
TABLE 5 Longitudinal mixed model examining the change





BASDAI 0.60 (0.44, 0.62)** 0.78 (0.65, 0.90)**
BASFI 0.53 (0.44, 0.62)** 0.60 (0.45, 0.69)**
BASMI 0.15 (0.02, 0.32)* 0.51 (0.29, 0.73)**
Time 0.00 (0.02, 0.01) 0.01 (0.01, 0.03)
Mixed models. All models are univariable and include vari-
ables at all time points stratified for individuals and
adjusted for time. A 1 unit increase in BASDAI is associ-
ated with an increase in the SSS of 0.6 points. *P<0.1,
**P<0.001.








atology/article/60/9/4121/6065947 by guest on 06 Septem
ber 2021
questionnaires may have been weakened by the time
gap between the visit and the return of the question-
naire, which was a maximum of 4 months in this study.
Despite the logistical issues, we have to acknowledge
that the chief challenge of the article concerns the use
of the FSDC to signify the presence or absence and de-
velopment of or recovery from FM. The FSDC have not
been validated in axSpA populations, but the 2016
FSDC may be used in populations with other conditions,
including musculoskeletal disorders [15]. For a clinical
diagnosis of FM in individual patients it is important to
also gather medical and social information.
The lack of physical signs by which disease activity in
FM or axSpA may be assessed [18] is an additional
challenge in interpreting the results of this article. We
thus have to bear in mind that there might be some
cross-contamination of patient-reported outcomes,
whereby high axSpA disease activity is registered as a
high WPI, while FM disease activity could inflate the
BASDAI. Indeed, a previous paper from this cohort
found that the average difference in BASDAI score be-
tween patients who did and did not have comorbid FM
was 1.04 (95% CI 0.88, 1.33) [8]. The BASDAI covers fa-
tigue, morning stiffness and axial and entheseal pain
[19], while the BASFI consists of 10 questions that cover
everyday physical functioning [20]. In mixed models
exploring the relationship between SpA and FM disease
activity we found that BASDAI and BASFI scores are
highly and significantly associated with both the SSS
and WPI. The overlap between the questions covered
by the BASDAI, SSS and WPI has previously been noted
[7], and the BASFI also contains questions of functions
that are impacted by fatigue. A study by Salaffi et al.
[21] reported that there was not any statistical difference
in BASDAI scores between patients who were diag-
nosed with axSpA and patients with FM alone. The Bath
indices are the most commonly used measures of
axSpA disease activity and are endorsed as core out-
come measures in axSpA by the ASAS [22].
Our study also highlights the limitations of the FM and
axSpA diagnostic criteria, as neither the 2016 FSDC nor
the ASAS criteria are ‘gold standard’ instruments with a
high level of specificity. A study by Barakliakos et al.
[25] found that as many as 29% of AS and 19% of non-
radiographic SpA patients fulfilled the 2010 FSDC.
Indeed, TNFi treatment for patients with non-
radiographic axSpA was originally denied by the US
Food and Drug Administration due to concern about the
specificity of the non-radiographic axSpA criteria [7, 25].
Our model for FM development was therefore stratified
according to classification criteria and was confirmed in
both patients who did and did not meet the mNY
criteria.
The association between baseline high levels of
axSpA disease activity and the development of FM may
be explained by the causal link between nociceptive
stimuli and central sensitization [28]. AxSpA disease ac-
tivity causes nociceptive pain, and central sensitization
is an essential feature of FM. FM might therefore have
developed as a long-term consequence of axSpA dis-
ease activity. This explanatory path is also supported by
our findings that in subgroup analyses, BASDAI scores
seem to be more strongly associated with FM develop-
ment in patients not receiving TNFi and that starting on
a TNFi was associated with FM recovery.
For patients and clinicians worried about the develop-
ment of FM in axSpA, our article implies that the
patients with high BASDAI and WPI scores are at the
highest risk of fulfilling the FSDC. Conversely, starting a
TNFi, together with a lower Ankylosing Spondylitis
Disease Activity Score (ASDAS) and WPI score, is asso-
ciated with recovery from FM. The clinician should keep
in mind that an unexpectedly high axSpA disease activ-
ity might have captured FM disease activity and that
disentangling the two is necessary in order to target the
therapy, while also considering the possibility of mis-
diagnosis. The knowledge that 50% of patients who ful-
filled the FSDC at baseline did not fulfil the criteria after
2 years may give hope to patients suffering from FM,
although we have to acknowledge that there was no
overall trend of improving SSS or WPI scores in this
study.
In summary, the current study shows that in patients
with axSpA, high levels of axSpA activity and the pres-
ence of widespread pain are associated with the devel-
opment of FM, while low levels of the same variables
are associated with recovery from FM. The presence of
comorbid FM should be considered in patients with a
history of high SpA disease activity and widespread
pain.
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